- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02041767
Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration (ERTAPRO)
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
Ertapenem is an antibiotic belonging to carbapenems family and used in infections with Gram-negative bacilli with extended spectrum beta lactamase (ESBL). Its efficacy has been demonstrated in abdominal, soft tissue, pulmonary, skin and gynaecological infections. Recently it has been compared to ceftriaxone in urinary infections demonstrating his efficacy and tolerance.
The purpose of this study is to assess its benefit in probabilistic strategy by demonstrating its prostatic diffusion in significant concentration when administrated in a pre-operative single injection.
Patients were divided in two groups receiving a single injection of 1g of ertapenem 1h or 12h before endoscopic surgery of prostate hyperplasia.
Concentration of ertapenem was measuring on blood sample and on chips resection of prostate during endoscopic surgery.
To demonstrate the prostatic diffusion in significant amount of ertapenem, the prostatic concentration of ertapenem had to be higher than the minimal inhibitory concentration (MIC) for 40% of the time of injection interval.
Type d'étude
Inscription (Anticipé)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
-
Paris, France, 75908 Cedex 15
- HEGP Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Acceptance and understanding of the consent form (signed)
- 18-80 years old patients
- BPH needing endoscopic resection according to French Urology Association recommendations
- Procedure and follow up made in investigator center
- normal digital rectal examination
- PSA :
- patient > 69 years old, not necessary
- patient < 69 years old, PSA<20 and if 4<PSA<20, the ratio free PSA/total PSA must be >10%
- patient with renal clearance >60 estimated with MDRD
- patient affiliated to the social security
Exclusion Criteria:
- personal or familial history of prostatic or genito-urinary cancer
- personal history of pelvic irradiation
- personal history of hormone-therapy
- personal history of prostatic adenomectomy by abdominal approach
- personal history of allergy to beta-lactamines
- urinary tract infection or bacterial colonisation at the time of procedure
- carbapenems treatment in the two weeks before surgery
- hyperresponsivness to ertapenem or other carbapenems antibiotic
- patient with renal clearance estimated with MDRD <60
- patient with catheter or probe permanently
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: group A
One single perfusion of 1g of ertapenem 1 hour prior to prostate surgical resection
|
One single injection of 1g of ertapenem before surgery
|
Expérimental: group B
One single perfusion of 1g of ertapenem 12 hour prior to prostate surgical resection
|
One single injection of 1g of ertapenem before surgery
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Prostatic concentration of ertapenem
Délai: at the time of surgery
|
To observe whether a significant intra-prostatic concentration of ertapenem can be obtained after a pre-operative single administration.
|
at the time of surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Prostatic concentration of ertapenem
Délai: at the time of surgery
|
To observe the difusion of ertapenem by comparing 1h versus12h injection prior to surgery
|
at the time of surgery
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Olivier Lortholary, Md, PhD, Service de Maladies Infectieuses et Tropicales, Hôpital Necker, 149 rue de Sèvres
- Chercheur principal: Marc-Olivier Timsit, Md, PhD, Service d'Urologie, HEGP, 20 rue Leblanc, 75015 Paris, France.
Publications et liens utiles
Publications générales
- Tomera KM, Burdmann EA, Reyna OG, Jiang Q, Wimmer WM, Woods GL, Gesser RM; Protocol 014 Study Group. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002 Sep;46(9):2895-900. doi: 10.1128/AAC.46.9.2895-2900.2002.
- Alhambra A, Cuadros JA, Cacho J, Gomez-Garces JL, Alos JI. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother. 2004 Jun;53(6):1090-4. doi: 10.1093/jac/dkh218. Epub 2004 Apr 29.
- Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods GL, Gesser RM; Protocol 021 Study Group. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology. 2002 Jul;60(1):16-22. doi: 10.1016/s0090-4295(02)01664-3.
- Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii67-74. doi: 10.1093/jac/dkh208.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- P090205
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Ertapenem
-
Henry Ford Health SystemRetiré
-
University Hospital, BordeauxComplété
-
Sihuan Pharmaceutical Holdings Group Ltd.ComplétéInfection urinaire compliquée, y compris pyélonéphrite aiguëChine
-
Daniel BenjaminRésilié
-
A.O. Ospedale Papa Giovanni XXIIIInconnueAppendicite aiguë sans péritoniteItalie
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.InconnuePneumonie communautaire acquiseChine
-
William Beaumont HospitalsWayne State UniversityComplétéPhase terminale de la maladie rénaleÉtats-Unis
-
National University Hospital, SingaporeMerck Sharp & Dohme LLCInconnueInfections des voies urinairesSingapour
-
Instituto Nacional de Cancer, BrazilRésiliéInfections des voies urinairesBrésil